OrganoidXplore

Features and Purpose: This screening service enables the thorough examination of a wide range of cancer models, anchored by a comprehensive library of Patient-Derived Organoid (PDO) and Patient-Derived Xenograft Organoid (PDXO) models with detailed mutational landscapes.

It offers a systematic approach to quantifying drug effects on both tumor and normal tissue organoids, enhancing the understanding of therapeutic impacts.

Features or Benefits:

• Measure tumor drug response in both tumor and normal organoids
• Explore new indications with validated targets
• Benefit from inclusion of 9 normal models, including 7 matched normal/disease pairs for comprehensive analysis
• Access 100+ well-characterized PDO and PDXO models for enhanced precision
• Representing clinically relevant mutational profiles, including KRAS, BRAF, BRCA 1 and 2, and EGFR
• Quantify cell viability and explore potential drug combinations

Applications:

• Fast-track your oncology drug development with results from 100+ models
• Identify your lead compound(s), stratify patients into responders, partial responders, and non-responders or preselect models for follow up studies in vitro/in vivo.